Argenx Se Stock Price, News & Analysis

On June 1, 2021, argenx announced the appointment of Mr. Karl Gubitz as Chief Financial Officer, succeeding Eric Castaldi, who will remain until June 30, 2021. Gubitz, with nearly 20 years of experience in global pharmaceutical finance, previously held a Vice President role at Pfizer. His expertise is expected to strengthen argenx's strategic financial direction as the company approaches the anticipated commercial launch of its lead product, efgartigimod. Gubitz's appointment comes during a pivotal time for the company, enhancing its position in the immunology sector.

argenx (Euronext & Nasdaq: ARGX) announced management's participation in several upcoming investor conferences. Key events include the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, JMP Securities Life Sciences Conference on June 16, J.P. Morgan European Healthcare Conference on June 17, and Raymond James Human Health Innovation Conference on June 22, 2021. The company focuses on developing treatments for severe autoimmune diseases and cancer, including efgartigimod and cusatuzumab.

argenx reported strong first-quarter 2021 results with revenue soaring to $158 million, a significant increase from $21 million in Q1 2020. The company announced that the Japanese Marketing Authorization Application for efgartigimod was accepted for review, following similar FDA acceptance in the U.S. with a target decision date of December 17, 2021. The firm is advancing registrational trials across multiple indications and plans to initiate two additional indications this year. Cash and equivalents reached $2.9 billion, bolstered by a public offering that raised $1.15 billion.

On May 11, 2021, argenx SE held its Annual General Meeting of Shareholders where all proposed resolutions were passed. Key decisions included the appointment of Yvonne Greenstreet and re-appointment of Anthony Rosenberg as non-executive directors for four-year terms. The Board was authorized to issue additional shares up to 10% of share capital for 18 months. The 2020 remuneration report and new remuneration policy were approved, and Deloitte Accountants B.V. was appointed as the auditor for 2021. Dr. David Lacey resigned from the Board but will serve in an advisory role.

argenx (Euronext & Nasdaq: ARGX) will host a conference call and audio webcast on May 14, 2021, at 2:30 p.m. CET (8:30 a.m. ET) to discuss its Q1 2021 financial results and present a business update.

Investors can access the call via the Investors section of the argenx website. The company is focused on advancing innovative antibody therapies for severe autoimmune diseases and cancer.

argenx (Euronext & Nasdaq: ARGX), a global immunology company, announced management participation in two upcoming conferences. The Kempen Life Sciences Conference will include investor meetings on May 5, 2021, while a BofA Securities Virtual Healthcare Conference will feature a fireside chat on May 13, 2021, at 8:00 a.m. ET. The company focuses on developing treatments for severe autoimmune diseases and cancer, working with leading researchers through its Immunology Innovation Program.

argenx SE has announced its annual general meeting scheduled for May 11, 2021, at the Hilton Amsterdam Airport. The meeting will include discussions on the 2020 Annual Accounts, the company's remuneration report, and the discharge of directors. Shareholders are encouraged to vote by proxy due to COVID-19. Important agenda items include approval of an updated remuneration policy and the appointment of new board members. The full agenda and relevant documents are available on the argenx website.

The FDA has accepted the Biologics License Application for IV efgartigimod, targeting generalized myasthenia gravis (gMG). This marks a significant milestone for argenx as it prepares for a commercial launch, anticipated in 2021.

Financial results reveal a revenue drop to €36.4 million in 2020, down €33.4 million from 2019. Operating expenses surged, leading to a total operating loss of €417.8 million. Despite losses, cash and equivalents increased to €1.63 billion, primarily due to a successful global offering. Increased spending is expected in 2021 due to expansion initiatives.

argenx announced the FDA's acceptance of its Biologics License Application (BLA) for efgartigimod to treat generalized myasthenia gravis (gMG). If approved, efgartigimod will be the first FcRn antagonist on the market, with a target action date set for December 17, 2021. The pivotal Phase 3 ADAPT trial showed that 67.7% of treated patients met the primary endpoint, significantly outperforming placebo (29.7%). A pre-approval access program has been launched in the U.S. for eligible gMG patients. argenx plans to submit applications to the EMA and Japan's PMDA later in 2021.